Recently, the S&P Global Corporate Sustainability Assessment (CSA) successively announced the 2024 Environmental, Social, and Governance (ESG) rating results. In 2024, Sino Biopharm's (01177.HK) CSA score ranked in the top 4% globally, achieving continuous improvement for three consecutive years. The latest score is 68, an increase of 15 points from the previous year. This achievement not only signifies the recognition of Sino Biopharm's work in the field of sustainable development by professional ESG rating agencies but also reflects the Group's growing competitiveness and influence on a global scale.

Sino Biopharm has always adhered to the path of sustainable development and continues to pay close attention to the changes and developments in the global field of sustainable development. Since 2022, the Group has benchmarked against leading international ESG management practices, achieving the scientific formulation of its ESG strategy, the comprehensive improvement of its ESG system, the special promotion of key ESG actions, and the deepened dissemination of the ESG concept. Most critically, under the guidance of the Board of Directors and the ESG strategy, the Group has focused on the four main pillars of "Cure", "Accessible", "Relationship", and "Environmental". It has promoted multiple innovative ESG governance enhancement projects, including the formulation of medical accessibility strategies, carbon neutrality goal and pathway planning, employee stock ownership plans, responsible supply chain construction, and climate risk response, thereby practically improving the Group's ESG management level.

2024 is the final year of the Group's first three-year ESG plan. Sino Biopharm has received recognition from multiple domestic and international authoritative institutions in the ESG field. While its S&P CSA score has continuously improved, its MSCI ESG rating has been A for two consecutive years, and its Wind ESG rating has reached AA. On this basis, it was also included in the FTSE4Good Index Series.

In 2025, Sino Biopharm's ESG work will be guided by the principles of "supporting strategic development and high-quality operations". It will fully launch its second three-year ESG plan, promoting special projects including carbon neutrality practices, climate risk response, DE&I (Diversity, Equity & Inclusion) culture construction, and responsible supply chain extension. It will continue to refine its own ESG management level, provide a guarantee for the company's sustainable development, and contribute to the global health cause.